Frog Gut Bacterium Eliminates Colorectal Cancer Tumors in Mice With Single Dose

Breakthrough Study: A Single Intravenous Dose of Ewingella americana Achieves 100% Complete Response in Colorectal Cancer Model

In a groundbreaking study published in the journal Gut Microbes, scientists at the Japan Advanced Institute of Science and Technology (JAIST) have identified a naturally occurring bacterium from the intestines of Japanese tree frogs that completely eliminated colorectal cancer tumors in mice with a single dose. This discovery represents a potential paradigm shift in how we approach cancer treatment, moving beyond traditional chemotherapy and immunotherapy toward living bacterial therapies that actively seek out and destroy cancer cells.

The research team, led by scientists at JAIST, isolated 45 bacterial strains from the intestines of Japanese tree frogs (Dryophytes japonicus), Japanese fire belly newts (Cynops pyrrhogaster), and Japanese grass lizards (Takydromus tachydromoides). After rigorous screening, nine strains showed anticancer activity, but one emerged as a standout performer: Ewingella americana.

100% Complete Response in Animal Models

In a controlled mouse model of colorectal cancer, a single intravenous dose of E. americana produced a 100% complete response rate, meaning all detectable tumors were eliminated. This result surpassed the effectiveness of standard therapies used for comparison, including immune checkpoint inhibitors (anti-PD-L1 antibody) and the chemotherapy drug liposomal doxorubicin.

While the findings are limited to animal models, the researchers describe the results as an encouraging proof of concept that could fundamentally change how bacterial therapies are developed for human cancer treatment.

How the Bacterium Attacks Cancer: A Dual Mechanism

The bacterium appears to fight cancer through two complementary mechanisms that work simultaneously, creating a powerful anti-tumor effect.

Direct Tumor Attack

E. americana is a facultative anaerobic bacterium, meaning it thrives in both oxygen-rich and oxygen-poor environments. This unique characteristic allows it to multiply inside the oxygen-deprived regions commonly found within solid tumors. Within 24 hours of treatment, the bacterial population inside tumors increased by roughly 3,000-fold, directly damaging and destroying cancer cells.

Immune System Activation

Alongside its direct effects, the bacterium stimulates a potent immune response. Its presence attracts key immune cells\u2014including T cells, B cells, and neutrophils\u2014directly into the tumor microenvironment. These immune cells then release inflammatory signaling molecules such as TNF-\u03b1 and IFN-\u03b3, which strengthen the body\u2019s natural immune response and promote cancer cell death.

Remarkable Tumor Specificity

One of the most striking findings of the study was that E. americana accumulated almost exclusively inside tumors and did not colonize healthy organs. The researchers attribute this tumor-specific targeting to several factors:

• Low oxygen environment: Tumors contain hypoxic (low-oxygen) regions that encourage bacterial growth.
• CD47 protein: Cancer cells produce CD47, which suppresses local immune activity and creates conditions that allow bacteria to survive.
• Leaky blood vessels: Tumor blood vessels are unusually permeable, making it easier for circulating bacteria to enter tumor tissue.
• Metabolic changes: Tumor-specific metabolic changes provide nutrients that support bacterial growth within the tumor.

Together, these characteristics allow the bacteria to concentrate precisely where tumors are located while avoiding healthy tissues\u2014a level of specificity that many cancer drugs fail to achieve.

Safety Profile: Rapid Clearance and No Chronic Toxicity

The research team also conducted thorough safety assessments. The bacteria were rapidly cleared from the bloodstream with a half-life of approximately 1.2 hours and became completely undetectable within 24 hours. No bacterial colonization was detected in healthy organs including the liver, spleen, lungs, kidneys, or heart.

The treatment caused only mild, temporary inflammation that resolved within 72 hours. During a 60-day observation period, researchers found no evidence of chronic toxicity, suggesting the therapy is well-tolerated even at effective doses.

Beyond Colorectal Cancer: Potential Applications

The study establishes proof of concept for using naturally occurring bacteria as a cancer therapy. Future research will examine whether the approach can be applied to additional solid tumors, including:

• Breast cancer
• Pancreatic cancer
• Melanoma
• Other solid tumors with hypoxic microenvironments

The team also plans to optimize treatment methods through dose fractionation and direct injection into tumors, and investigate whether E. americana works even better when combined with existing chemotherapy or immunotherapy regimens.

Frequently Asked Questions

What is Ewingella americana?

Ewingella americana is a naturally occurring bacterium found in the intestines of Japanese tree frogs. It belongs to the Enterobacteriaceae family and has demonstrated remarkable anticancer properties in laboratory studies.

Is this treatment available for humans?

No. This research is currently limited to mouse models. Human clinical trials would be required before this could become an available treatment. The researchers describe these findings as an encouraging proof of concept that warrants further investigation.

How does the bacterium target only cancer cells and not healthy tissue?

The bacterium accumulates almost exclusively inside tumors due to several factors: the low-oxygen environment inside tumors, the CD47 protein produced by cancer cells that suppresses local immunity, the leaky nature of tumor blood vessels, and tumor-specific metabolic changes that provide nutrients for bacterial growth.

What makes this different from existing cancer treatments?

Unlike conventional chemotherapy that affects both healthy and cancerous cells, this bacterial therapy actively seeks out tumors, accumulates specifically within them, and attacks through dual mechanisms\u2014direct killing and immune activation. This targeted approach potentially offers greater efficacy with fewer side effects.

Could this approach work for other types of cancer?

Researchers plan to investigate the approach for breast cancer, pancreatic cancer, melanoma, and other solid tumors. The bacterium\u2019s ability to thrive in low-oxygen environments makes it potentially suitable for any solid tumor that contains hypoxic regions.

When will human clinical trials begin?

No timeline has been announced for human clinical trials. Further animal studies and safety assessments are needed before any human trials can be planned.

This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare providers regarding cancer treatment options.